WinSanTor
PrivateLast Round
SAFE
Apr 29, 2024
Est. Valuation
$25M
Total Funding Raised
$16.4M
Company Overview
WinSanTor is a clinical-stage biotechnology company focused on the discovery and development of treatments for peripheral neuropathies, including diabetic, chemotherapy-induced, and HIV-induced peripheral neuropathy.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
WinSanTor Comparables
Compare WinSanTor with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Regenacy Pharmaceuticals | 84% | |
| AlgoTx | 78% | |
| Novaremed AG | 78% |
WinSanTor Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| SAFE | Apr 29, 2024 | ||||
| Crowdfunding | Apr 1, 2024 | ||||
| Debt | Nov 1, 2023 | ||||
| SAFE | Oct 1, 2023 | ||||
| SAFE | Sep 1, 2023 | ||||
Debt | Jun 1, 2023 |
Key People
Founding team and executive leadership
WinSanTor Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Canadian Institutes of Health Research | Grant |
| National Cancer Institute | Grant |
| NIH RADx | Grant |
| Thynk Capital | VC Round |
| Methuselah Foundation | VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 13, 2026
Monthly visitors increased 48% MoM.
- Apr 1, 2024
$707K raised in crowdfunding round.
WinSanTor Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about WinSanTor's valuation, stock price, and market status.
Is WinSanTor a public or private company?
WinSanTor is a private company.
What is the current stock price of WinSanTor?
WinSanTor is a private company, so its shares have no public market price. Caplight tracks WinSanTor's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is WinSanTor worth (valuation)?
WinSanTor's valuation is estimated at $25.0M based on funding round data.
Can I buy WinSanTor stock?
WinSanTor shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was WinSanTor's last funding round?
WinSanTor's most recent funding round was SAFE on April 29, 2024.
Who are the main investors in WinSanTor?
Key investors in WinSanTor include NIH RADx.
Will WinSanTor IPO soon?
No public IPO plans have been announced for WinSanTor.
How can I track WinSanTor secondary market activity?
Caplight tracks bids, offers, and trades in WinSanTor's shares on secondary markets.